Emerging drugs for essential thrombocythemia

References

• Srour SA, Devesa SS, Morton LM, et al. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12. Br J Haematol. 2016 Aug;174(3):382–396. PubMed PMID: 27061824; PubMed Central PMCID: PMCPMC4961550. eng.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Silverstein MN, Jacobsen SJ, et al. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. Am J Hematol. 1999 May;61(1):10–15. PubMed PMID: 10331505; eng.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Fonseca R, Pereira DL, et al. A long-term retrospective study of young women with essential thrombocythemia. Mayo Clin Proc. 2001 Jan;76(1):22–28. PubMed PMID: 11155408; eng.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014 Oct 16;124(16):2507–13; quiz 2615. PubMed PMID: 25037629; PubMed Central PMCID: PMCPMC4199952. eng.
   Web of Science ®Google Scholar
• Ma X, Vanasse G, Cartmel B, et al. Prevalence of polycythemia vera and essential thrombocythemia. Am J Hematol. 2008 May;83(5):359–362. PubMed PMID: 18181200; eng.
   PubMed Web of Science ®Google Scholar
• Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005 Apr;7(4):387–397. PubMed PMID: 15837627; eng.
   PubMed Web of Science ®Google Scholar
• Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013 Dec 19;369(25):2391–2405. PubMed PMID: 24325359; PubMed Central PMCID: PMCPMC3966280. eng.
   PubMed Web of Science ®Google Scholar
• Cabagnols X, Favale F, Pasquier F, et al. Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood. 2016 Jan 21;127(3):333–342. PubMed PMID: 26450985; eng.
   PubMed Web of Science ®Google Scholar
• Milosevic Feenstra JD, Nivarthi H, Gisslinger H, et al. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood. 2016 Jan 21;127(3):325–332. PubMed PMID: 26423830; PubMed Central PMCID: PMCPMC4752213. eng.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 May 19;127(20):2391–2405. PubMed PMID: 27069254; eng
   PubMed Web of Science ®Google Scholar
• Michiels JJ. Acquired von Willebrand disease due to increasing platelet count can readily explain the paradox of thrombosis and bleeding in thrombocythemia. Clin Appl Thromb Hemost. 1999 Jul;5(3):147–151. PubMed PMID: 10725999; eng.
   PubMed Web of Science ®Google Scholar
• Barbui T, Vannucchi AM, Buxhofer-Ausch V, et al. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J. 2015 Nov 27;5:e369.
   PubMed Web of Science ®Google Scholar
• Carobbio A, Antonioli E, Guglielmelli P, et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol. 2008 Jun 1;26(16):2732–2736. PubMed PMID: 18443353; eng.
   PubMed Web of Science ®Google Scholar
• Valera MC, Parant O, Vayssiere C, et al. Essential thrombocythemia and pregnancy. Eur J Obstet Gynecol Reprod Biol. 2011 Oct;158(2):141–147. PubMed PMID: 21640467; eng.
   PubMed Web of Science ®Google Scholar
• Barosi G, Mesa R, Finazzi G, et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013 Jun 06;121(23):4778–4781. PubMed PMID: 23591792; PubMed Central PMCID: PMCPmc3674675. eng.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007 Jan 1;109(1):68–76. PubMed PMID: 17123268; eng.
   PubMed Web of Science ®Google Scholar
• Hernandez-Boluda JC, Pereira A, Cervantes F, et al. Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide. Ann Hematol. 2013 Jun;92(6):771–775. PubMed PMID: 23354997; eng.
   PubMed Web of Science ®Google Scholar
• Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004 Jan 8;350(2):114–124. PubMed PMID: 14711910; eng.
   PubMed Web of Science ®Google Scholar
• Alvarez-Larran A, Pereira A, Guglielmelli P, et al. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Haematologica. 2016 Aug;101(8):926–931. PubMed PMID: 27175028; PubMed Central PMCID: PMCPMC4967571. eng.
   PubMed Web of Science ®Google Scholar
• Michiels JJ, Berneman Z, Schroyens W, et al. Platelet-mediated thrombotic complications in patients with ET: reversal by aspirin, platelet reduction, and not by coumadin. Blood Cells Mol Dis. 2006 Mar-Apr;36(2):199–205. PubMed PMID: 16510297; eng.
   PubMed Web of Science ®Google Scholar
• Godfrey AL, Campbell PJ, MacLean C, et al. Hydroxycarbamide plus aspirin vs aspirin alone in intermediate risk essential thrombocythemia: results of the PT-1 international, prospective, randomized clinical trial. Blood Cancer J. 2017;130:319.
   Google Scholar
• Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995 Apr 27;332(17):1132–1136. PubMed PMID: 7700286; eng.
   PubMed Web of Science ®Google Scholar
• Antonioli E, Guglielmelli P, Pieri L, et al. Hydroxyurea-related toxicity in 3,411 patients with Ph’-negative MPN. Am J Hematol. 2012 May;87(5):552–554. PubMed PMID: 22473827; eng.
   PubMed Web of Science ®Google Scholar
• Sterkers Y, Preudhomme C, Lai JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood. 1998 Jan 15;91(2):616–622. PubMed PMID: 9427717; eng.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004 Nov 15;117(10):755–761. PubMed PMID: 15541325; eng.
   PubMed Web of Science ®Google Scholar
• Tomer A. Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia. Blood. 2002 Mar 1;99(5):1602–1609. PubMed PMID: 11861274; eng.
   PubMed Web of Science ®Google Scholar
• Murphy S. Therapeutic dilemmas: balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD). Thromb Haemost. 1997 Jul;78(1):622–626. PubMed PMID: 9198227; eng.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33–45. PubMed PMID: 16000354; eng.
   PubMed Web of Science ®Google Scholar
• Gisslinger H, Gotic M, Holowiecki J, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar 7;121(10):1720–1728. PubMed PMID: 23315161; PubMed Central PMCID: PMCPMC3591796. eng.
   PubMed Web of Science ®Google Scholar
• Petrides PE, Schoergenhofer C, Widmann R, et al. Pharmacokinetics of a novel anagrelide extended-release formulation in healthy subjects: food intake and comparison with a reference product. Clin Pharmacol Drug Dev. 2018 Feb;7(2):123–131. PubMed PMID: 28301098; PubMed Central PMCID: PMCPMC5811889. eng.
   PubMed Web of Science ®Google Scholar
• Steurer M, Gastl G, Jedrzejczak WW, et al. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Cancer. 2004 Nov 15;101(10):2239–2246. PubMed PMID: 15476273; eng.
   PubMed Web of Science ®Google Scholar
• Birgegard G, Besses C, Griesshammer M, et al. Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the evaluation of anagrelide efficacy and long-term safety study. Haematologica. 2018 Jan;103(1):51–60. PubMed PMID: 29079600; PubMed Central PMCID: PMCPMC5777190. eng.
   PubMed Web of Science ®Google Scholar
• Kanakura Y, Shirasugi Y, Yamaguchi H, et al. A phase 3b, multicenter, open-label extension study of the long-term safety of anagrelide in Japanese adults with essential thrombocythemia. Int J Hematol. 2018 Nov;108(5):491–498. 10.1007/s12185-018-2510-7. PubMed PMID: 30121892; eng.
   PubMed Web of Science ®Google Scholar
• Rey J, Viallard JF, Keddad K, et al. Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France. Eur J Haematol. 2014 Feb;92(2):127–136. PubMed PMID: 24118452; PubMed Central PMCID: PMCPMC4232889. eng.
   PubMed Web of Science ®Google Scholar
• Barosi G, Besses C, Birgegard G, et al. A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia. 2007 Feb;21(2):277–280. PubMed PMID: 17251900; eng.
   PubMed Web of Science ®Google Scholar
• Christoforidou A, Pantelidou D, Anastasiadis A, et al. Hydroxyurea and anagrelide combination therapy in patients with chronic myeloproliferative diseases resistant or intolerant to monotherapy. Acta Haematol. 2008;120(4):195–198. PubMed PMID: 19129692; eng.
   PubMed Web of Science ®Google Scholar
• Pugliese NML, Gherghi M, Quintarelli C, et al. Anagrelide in monotherapy or combined with hydroxyurea yields a high rate of complete response in essential thrombocythemia. Haematologica. 2012;97(Suppl1):641. (Abstract 1632).
   PubMedGoogle Scholar
• Ahn INE, Rice L. Combination treatment of essential thrombocythemia with hydroxyurea and anagrelide. Blood. 2011;118:517.
   Google Scholar
• Micheletti MDAM, Drera M, Ferrari S, et al. the combined use of hydroxyurea and anagrelide allows better hematologic control in patients with chronic myeloproliferative disorders and thrombocytosis. a report on 13 patients with poor tolerance to hydroxyurea monotherapy. Blood. 2006;108:4892.
   Web of Science ®Google Scholar
• D’Adda M, Micheletti M, Drera M, et al. The combined use of hydroxyurea and anagrelide allows satisfactory hematologic control in patients with chronic myeloproliferative disorders and thrombocytosis: a report on 13 patients with poor tolerance to hydroxyurea monotherapy. Leuk Lymphoma. 2008 Nov;49(11):2216–2218. PubMed PMID: 19021067; eng.
   PubMed Web of Science ®Google Scholar
• Gugliotta L, Besses C, Griesshammer M, et al. Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study. Haematologica. 2014 Apr;99(4):679–687. PubMed PMID: 24334294; PubMed Central PMCID: PMCPMC3971078. eng.
   PubMed Web of Science ®Google Scholar
• Evaluation of two antineoplastic agents, PIPOBROMAN (vercyte) and thioguanine. JAMA. 1967 May 15;200(7):619–620. PubMed PMID: 5228673; eng.
   Google Scholar
• Mazzucconi MG, Francesconi M, Chistolini A, et al. Pipobroman therapy of essential thrombocythemia. Scand J Haematol. 1986 Oct;37(4):306–309. PubMed PMID: 3787181; eng.
   PubMedGoogle Scholar
• Barbui TGA, Masciulli A, Carobbio A, et al. risk factors for secondary cancer in a case-control study on 1,259 patients with myeloproliferative neoplasms. Blood. 2018;132:4279.
   Web of Science ®Google Scholar
• De Sanctis V, Mazzucconi MG, Spadea A, et al. Long-term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman: occurrence of leukaemic evolution. Br J Haematol. 2003 Nov;123(3):517–521. PubMed PMID: 14617017; eng.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010 Sep 16;363(12):1117–1127. PubMed PMID: 20843246; eng.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017 Feb 22;10(1):55. 10.1186/s13045-017-0417-z. PubMed PMID: 28228106; PubMed Central PMCID: PMCPMC5322633. eng.
   PubMedGoogle Scholar
• Passamonti F, Griesshammer M, Palandri F, et al. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol. 2017 Jan;18(1):88–99. PubMed PMID: 27916398; eng.
   PubMed Web of Science ®Google Scholar
• Silver RT, Kiladjian JJ, Hasselbalch HC. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Rev Hematol. 2013 Feb;6(1):49–58. PubMed PMID: 23373780; eng
   PubMed Web of Science ®Google Scholar
• Ferrantini M, Capone I, Belardelli F. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie. 2007 Jun-Jul;89(6–7):884–893. PubMed PMID: 17532550; eng.
   PubMed Web of Science ®Google Scholar
• Silver RT, Vandris K. Recombinant interferon alpha (rIFN alpha-2b) may retard progression of early primary myelofibrosis. Leukemia. 2009 Jul;23(7):1366–1369. PubMed PMID: 19440212; eng.
   PubMed Web of Science ®Google Scholar
• Masarova L, Yin CC, Cortes JE, et al. Histomorphological responses after therapy with pegylated interferon alpha-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Exp Hematol Oncol. 2017;6:30. PubMed PMID: 29152412; PubMed Central PMCID: PMCPMC5679503. eng.
   PubMed Web of Science ®Google Scholar
• Masarova L, Patel KP, Newberry KJ, et al. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. Lancet Haematol. PubMed PMID: 28291640; eng Mar 10 2017. DOI:10.1016/s2352-3026(17)30030-3.
   PubMed Web of Science ®Google Scholar
• Guerini V, Barbui V, Spinelli O, et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia. 2008 Apr;22(4):740–747. PubMed PMID: 18079739; eng.
   PubMed Web of Science ®Google Scholar
• Spanoudakis E, Bazdiara I, Pantelidou D, et al. Dynamics of telomere’s length and telomerase activity in Philadelphia chromosome negative myeloproliferative neoplasms. Leuk Res. 2011 Apr;35(4):459–464. PubMed PMID: 20828816; eng.
   PubMed Web of Science ®Google Scholar
• Wang X, Hu CS, Petersen B, et al. Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells. Blood Adv. 2018 Sep 25;2(18):2378–2388. PubMed PMID: 30242099; PubMed Central PMCID: PMCPMC6156882. eng.
   PubMed Web of Science ®Google Scholar
• Iancu-Rubin C, Mosoyan G, Glenn K, et al. Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis. Exp Hematol. 2014 Feb;42(2):137–45.e5. PubMed PMID: 24309210; eng.
   PubMed Web of Science ®Google Scholar
• Lu M, Wang X, Li Y, et al. Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-alpha 2a specifically targets JAK2V617F-positive polycythemia vera cells. Blood. 2012 Oct 11;120(15):3098–3105. PubMed PMID: 22872685; PubMed Central PMCID: PMCPMC3471518. eng.
   PubMed Web of Science ®Google Scholar
• Lu M, Xia L, Li Y, et al. The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon alpha 2a target JAK2V617F-positive progenitor and stem cells. Blood. 2014 Jul 31;124(5):771–779. PubMed PMID: 24869939; PubMed Central PMCID: PMCPMC4467881. eng.
   PubMed Web of Science ®Google Scholar
• Troung PVSM, Bessudo A, Jawien W, et al. Final results of anagrelide controlled-release (GALE-401) safety, efficacy and pharmacokinetics in subjects with myeloproliferative neoplasms (MPN)-related thrombocytosis. Blood. 2015;126:4074.
   Web of Science ®Google Scholar
• Verstovsek SSM, Dakhil S, Lee J, et al. Anagrelide controlled release (GALE-401) safety profile consistently well tolerated in myeloproliferative neoplams patients and healthy volunteers. Vol. P675. EHA Learning Center Abs; 2016. p. 133563.[cited 2019 Mar]. Available from: https://learningcenter.ehaweb.org/eha/2016/21st/133563/srdan.verstovsek.anagrelide.controlled.release.28gale-40129.safety.profile.html 
   Google Scholar
• Gisslinger HRA, Karyagina E, Kyrcz-Krzemień S, et al. Phase 3 trial TEAM-ET in 106 high-risk Essential Thrombocythemia patients, demonstrating non-inferiority of Anagrelide Retard, a novel, extended-release anagrelide formulation, to the licensed comparator. European School of Hematology EHA 21st Congress, Denmark, Copenhagen. 2016.
   Google Scholar
• Gisslinger H, Buxhofer-Ausch V, Hodisch J, et al. A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia - the TEAM-ET 2.0 trial. Br J Haematol. 2019 Mar 28 PubMed PMID: 30919941; eng. DOI:10.1111/bjh.15824.
   Web of Science ®Google Scholar
• Gisslinger HKC, Abdulkadyrov K, Kyrcz-Krzemien S, et al. Final results from the phase 3 trial areta comparing a novel, extended-release anagrelide formulation to placebo in essential thrombocythemia patients with defined risk status. Blood. 2016;128:476.
   Web of Science ®Google Scholar
• Silver RT. Recombinant interferon-alpha for treatment of polycythaemia vera. Lancet. 1988 Aug 13;2(8607):403. PubMed PMID: 2899816; eng.
   PubMed Web of Science ®Google Scholar
• Langer C, Lengfelder E, Thiele J, et al. Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study. Haematologica. 2005 Oct;90(10):1333–1338. PubMed PMID: 16219569; eng.
   PubMed Web of Science ®Google Scholar
• Stegelmann F, Schauer S, Kirschbaum R, et al. Long-Term Interferon-α Treatment in Essential Thrombocythemia. Blood. 2015;126:4064.
   Web of Science ®Google Scholar
• Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, et al. Ropeginterferon alfa-2b, a novel IFNalpha-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015 Oct 8;126(15):1762–1769. PubMed PMID: 26261238; PubMed Central PMCID: PMCPmc4608390. eng.
   PubMed Web of Science ®Google Scholar
• Knudsen TA, Hansen DL, Ocias LF, et al. Interim analysis of the DALIAH TRIAL - a randomized controlled phase III clinical trial comparing recombinant interferon alpha 2 vs hydroxyurea in MPN patients. EHA Learning Centre. 2018 Jun 15. 214492, oral #S131.
   Google Scholar
• Pugliese NCI, Casoria A, Raimondo M, et al. Pegylated INTERFERON ALPHA-2B versus ΑLPHA-2A for the treatment of essential thrombocythemia: efficacy and safety profile. EHA Learning Center.  2018 Jun 16. 215658 Abstract: PS1358.
   Google Scholar
• Verger E, Cassinat B, Chauveau A, et al. Clinical and molecular response to interferon-alpha therapy in essential thrombocythemia patients with CALR mutations. Blood. 2015 Dec 10;126(24):2585–2591. PubMed PMID: 26486786; eng.
   PubMed Web of Science ®Google Scholar
• Yacoub A, Mascarenhas J, Kosiorek HE, et al. Single-arm salvage therapy with pegylated interferon alfa-2a for patients with high-risk polycythemia vera or high-risk essential thrombocythemia who are either hydroxyurea-resistant or intolerant: final results of the myeloproliferative disorders-research consortium (MPD-RC) protocol 111 global phase II trial. Blood. 2017;130:321.
   Web of Science ®Google Scholar
• Mascarenhas JKH, Prchal J, Rambaldi A, et al. Results of the myeloproliferative neoplasms - research consortium (MPN-RC) 112 randomized trial of pegylated interferon alfa-2a (PEG) versus hydroxyurea (HU) therapy for the treatment of high risk polycythemia vera (PV) and high risk essential thrombocythemia (ET). Blood. 2018;132:577.
   PubMed Web of Science ®Google Scholar
• Mesa RKH, Mascarenhas J, Prchal J, et al. Impact on MPN symptoms and quality of life of front line pegylated interferon alpha-2a Vs. hydroxyurea in high risk polycythemia vera and essential thrombocythemia: results of myeloproliferative disorders research consortium (MPD-RC) 112 global phase III trial. Blood. 2018;130:3032.
   Web of Science ®Google Scholar
• Them NC, Bagienski K, Berg T, et al. Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. Am J Hematol. 2015 Apr;90(4):288–294. PubMed PMID: 25545244; eng.
   PubMed Web of Science ®Google Scholar
• Gisslinger H, Klade C, Georgiev P, et al. Evidence for superior efficacy and disease modification after three years of prospective randomized controlled treatment of polycythemia vera patients with ropeginterferon Alfa-2b Vs. HU/BAT Blood. 2018;130:579.
   Google Scholar
• PharmaEssentia. PharmaEssentia and AOP orphan receive EU approval of besremi™ (Ropeginterferon Alfa-2b) for treatment of polycythemia vera (PV) in EU. 2018. [cited 2019 Apr]. Available from: https://www.prnewswire.com/news-releases/pharmaessentia-and-aop-orphan-receive-eu-approval-of-besremi-ropeginterferon-alfa-2b-for-treatment-of-polycythemia-vera-pv-in-eu-300800079.html.
   Google Scholar
• Gilreath JATT, Kim JS. Hickman K and Prchal J. Compassionate Use of Ropeginterferon-Alfa-2b/P1101 for Treatment of High Risk Polycythemia Vera and Essential Thrombocythemia Patients Previously Controlled on Pegylated Interferon-Alfa-2a/Pegasys®. Blood. 2018;132:5459.
   Web of Science ®Google Scholar
• Verstovsek S, Passamonti F, Rambaldi A, et al. Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. Blood. 2017 Oct 12;130(15):1768–1771. PubMed PMID: 28827411; PubMed Central PMCID: PMCPMC5639482. eng.
   PubMed Web of Science ®Google Scholar
• Pieri L, Pancrazzi A, Pacilli A, et al. JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib. Blood. 2015 May 21;125(21):3352–3353. PubMed PMID: 25999444; eng.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Mead AJ, Panchal A, et al. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood. 2017 Oct 26;130(17):1889–1897. PubMed PMID: 29074595; eng.
   PubMed Web of Science ®Google Scholar
• Berdeja J, Palandri F, Baer MR, et al. Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms. Leuk Res. 2018 Aug;71:82–88. PubMed PMID: 30025280; eng.
   PubMed Web of Science ®Google Scholar
• Moliterno AR, Hexner E, Roboz GJ, et al. An open-label study of CEP-701 in patients with JAK2 V617F-positive PV and ET: update of 39 enrolled patients. Blood. 2009;114:313–314, Abs 753
   Web of Science ®Google Scholar
• Verstovsek S, Courby S, Griesshammer M, et al. A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia. Leuk Res. 2017 Sep;60:11–17. PubMed PMID: 28622623; eng.
   PubMed Web of Science ®Google Scholar
• Mascarenhas JLM, Virtgaym E, Kosiorek H, et al. Open label phase i study of single agent oral RG7388 (idasanutlin) in patients with polycythemia vera and essential thrombocythemia. Blood. 2017;130:254.
   Web of Science ®Google Scholar
• Rambaldi A, Dellacasa CM, Finazzi G, et al. A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol. 2010 Aug;150(4):446–455. PubMed PMID: 20560970; eng.
   PubMed Web of Science ®Google Scholar
• Andersen CL, McMullin MF, Ejerblad E, et al. A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2013 Aug;162(4):498–508. PubMed PMID: 23758082; eng.
   PubMed Web of Science ®Google Scholar
• Baerlocher GM, Oppliger Leibundgut E, Ottmann OG, et al. telomerase inhibitor imetelstat in patients with essential thrombocythemia. N Engl J Med. 2015 Sep 3;373(10):920–928. PubMed PMID: 26332546; eng.
   PubMed Web of Science ®Google Scholar
• Porpaczy E, Tripolt S, Hoelbl-Kovacic A, et al. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. Blood. 2018;132(7):694–706. PubMed PMID: 30765499; eng. Blood. 2019 Feb 14;133(7):768. .
   PubMed Web of Science ®Google Scholar
• Pemmaraju N, Kantarjian H, Nastoupil L, et al. Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy. Blood. 2019 Feb 22 PubMed PMID: 30796023; eng. DOI:10.1182/blood-2019-01-897637.
   PubMed Web of Science ®Google Scholar